SAMR fines pharma company for refusal to deal
China’s competition watchdog has fined a drugmaker nearly €13 million for refusing to supply an active pharmaceutical ingredient to downstream companies.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.